View Clinical Trial (Medical Research Study)
Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study) - NCT00632411-78236(Clinical Trial 207628)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Lackland AFB |
|
State:
|
|
TX |
| Zip Code: |
|
78236 |
| Conditions: |
|
Smoking - Smoking Cessation |
| Purpose: |
|
Rates of cigarette smoking in the military are high. Tobacco telephone quit lines are
telephone-based services that provide information and guidance to people who want to quit
smoking. This study will evaluate the effectiveness of a tobacco quit line program, in
addition to nicotine replacement patches, at helping people in the military quit smoking
cigarettes.
|
| Study summary: |
|
Active duty military personnel are at high risk of cigarette smoking. Despite strong efforts
by the Department of Defense to reduce tobacco use, rates of smoking among people in the
military remain high. The military lifestyle presents unique challenges to implementing
smoking cessation programs, including the high mobility of troops, remote locations, and
limited access to healthcare services. Because of these challenges, many smoking cessation
programs that are effective in the non-military population are often ineffective in the
military population. Tobacco telephone quit lines are telephone-based tobacco cessation
services that provide easy access to educational materials, referrals to local programs, and
individualized telephone counseling. Because tobacco quit lines are remotely based and can
fit into varying schedules at convenient times, they may be effective among people in the
military. Nicotine replacement patches are another effective smoking cessation tool and can
be used in addition to telephone quit lines. The purpose of this study is to evaluate the
effectiveness of tobacco quit lines, in addition to nicotine replacement patches, at
improving smoking cessation rates among members of the Air Force.
This study will enroll active duty Air Force personnel who have smoked at least five
cigarettes a day in the year before study entry. Participants will be randomly assigned to
either a proactive group, in which study researchers will initiate contact with the
participants, or a reactive group, in which participants will initiate contact with the
researchers. In this four-session program, phone calls will occur at 1- to 2-week intervals
over an 8-week period. The phone sessions will focus on cutting down on cigarette smoking,
setting a quit date, and relapse prevention. All participants will receive nicotine
replacement patches after the second session is completed. At the end of session four and 1
year later, study staff will call participants to collect information on tobacco abstinence,
nicotine replacement patch use adherence, and other smoking cessation medication use. |
| Criteria: |
|
Inclusion Criteria:
- Active duty Air Force personnel
- Has smoked five or more cigarettes per day for at least 1 year before study entry
Exclusion Criteria:
- Known allergy or sensitivity to nicotine replacement therapy
- Does not own a telephone
- Pregnant or breastfeeding |
|
|
|
| Study is available at: |
|
Wilford Hall Medical Center Lackland AFB, TX 78236 United States
Primary Contact: Karen LeRoy, R.N. Email: kleroy1@uthsc.edu Phone: 210-292-3504
Secondary Contact: Phyllis A Richey, Ph.D. Email: prichey@uthsc.edu Phone: 901-448-5900 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 22, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|